Nano-engineering of ketorolac tromethamine platforms for ocular treatment of inflammatory disorders
| dc.contributor.author | Mallandrich Miret, Mireia | |
| dc.contributor.author | Calpena Campmany, Ana Cristina | |
| dc.contributor.author | Clares Naveros, Beatriz | |
| dc.contributor.author | Parra Coca, Alexander | |
| dc.contributor.author | García López, María Luisa | |
| dc.contributor.author | Soriano-Ruiz, José L. | |
| dc.contributor.author | Francisco Fernández-Campos | |
| dc.date.accessioned | 2021-02-25T07:02:53Z | |
| dc.date.available | 2022-02-15T06:10:19Z | |
| dc.date.issued | 2021-02-15 | |
| dc.date.updated | 2021-02-25T07:02:53Z | |
| dc.description.abstract | Aim: The development and optimization of Ketorolac tromethamine-loaded polylactic-co-glycolic acid nanoparticles (KT-NPs) for the treatment of inflammatory processes of the eye. Materials & methods: KT-NPs were developed by factorial design and characterized by assessing their physicochemical properties. Biopharmaceutical behavior studies, ocular tolerance, anti-inflammatory efficacy and bioavailability tests were performed on pigs. Results: Optimized KT-NPs of 112 nm, narrow distribution with encapsulation efficiency near 100% were obtained. KT release followed the Weibull model and there was significantly greater retention in the cornea and sclera than in the commercial reference. KT-NPs showed no signs of ocular irritancy and similar anti-inflammatory efficacy to the commercial reference. Conclusion: KT-NPs were a suitable alternative for the treatment of inflammatory disorders of the anterior and posterior segments of the eye as an alternative to conventional topical formulations. | |
| dc.format.mimetype | application/pdf | |
| dc.identifier.idgrec | 707250 | |
| dc.identifier.issn | 1743-5889 | |
| dc.identifier.uri | https://hdl.handle.net/2445/174286 | |
| dc.language.iso | eng | |
| dc.publisher | Future Medicine | |
| dc.relation.isformatof | Versió postprint del document publicat a: https://doi.org/10.2217/nnm-2020-0403 | |
| dc.relation.ispartof | Nanomedicine, 2021, vol. 13, num. 3 | |
| dc.relation.uri | https://doi.org/10.2217/nnm-2020-0403 | |
| dc.rights | (c) Future Medicine, 2021 | |
| dc.rights.accessRights | info:eu-repo/semantics/openAccess | |
| dc.source | Articles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica) | |
| dc.subject.classification | Oftàlmia | |
| dc.subject.classification | Agents antiinflamatoris | |
| dc.subject.classification | Nanopartícules | |
| dc.subject.classification | Administració de medicaments | |
| dc.subject.other | Ophthalmia | |
| dc.subject.other | Antiinflammatory agents | |
| dc.subject.other | Nanoparticles | |
| dc.subject.other | Administration of drugs | |
| dc.title | Nano-engineering of ketorolac tromethamine platforms for ocular treatment of inflammatory disorders | |
| dc.type | info:eu-repo/semantics/article | |
| dc.type | info:eu-repo/semantics/acceptedVersion |
Files
Original bundle
1 - 1 of 1